Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ADCY5 | O95622 | 8/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24465167 | 0.80 | ADCY5 (0.64) | ADCY5 | |
| SCHEMBL20434928 | 0.80 | ADCY5 (0.64) | ADCY5 | |
| SCHEMBL20434932 | 0.80 | ADCY5 (0.64) | ADCY5 | |
| SCHEMBL21392942 | 0.79 | ADCY5 (0.44) | FDPSADCY5ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL24276633 | 0.78 | ALDH1A1 (0.39) | FDPSALDH1A1 | |
| SCHEMBL21393219 | 0.77 | ADCY5 (0.44) | FDPSADCY5ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21393175 | 0.75 | ALDH1A1 (0.36) | ADCY5ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21393218 | 0.74 | ADCY5 (0.43) | FDPSADCY5ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19553770 | 0.73 | ADORA2A (0.49) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20434915 | 0.73 | ADCY5 (0.42) | ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019180683-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-26 | — | — | WO | disclosed |